Fig. 3

Deletion of Jarid2 does not recapitulate the functional advantages conferred by miR-155 in CD8⁺ T cells. a Sequence alignment of the Jarid2 3′ UTR in multiple species. The predicted miR-155 target site sequence is shown in capital bold. b Jarid2 protein level in miR-155-overexpressing cells assessed by Immunoblot. c Quantitative RT-PCR of Jarid2 mRNA in pmel-1 Jarid2^+/+ and pmel-1 Jarid2^–/– cells. Bars (mean ± s.e.m. of technical triplicates) are relative to Rpl13 mRNA. d Flow cytometry of splenic CD8⁺GFP⁺ T cells assessed at different time points following adoptive transfer of 3 × 10⁵ pmel-1 Jarid2^fl/fl CD8⁺ T cells transduced with GFP-Cre or Ctrl GFP into wild-type mice in conjunction with gp100-VV. Numbers indicate the percentage of cells after gating on live CD8⁺GFP⁺ T cells. e Number of splenic pmel-1 CD8⁺GFP⁺ T cells at day 5 after transfer as in d. Bars represent the mean ± s.e.m. of three individual mice. f Flow cytometry of splenic pmel-1 CD8⁺GFP⁺ T cells 5 days after transfer as described in d. Numbers indicate the percentage of cells after gating on live CD8⁺GFP⁺ T cells. g Percentage of splenic pmel-1 CD8⁺GFP⁺ T_E cells at indicated time points after transfer as in d. Data are presented as box plots extending to minimum and maximum values. Bands inside the boxes represent median values of three individual mice. h Tumor size (left, mean ± s.e.m.) and survival curve (right) of B16 tumor-bearing mice after adoptive transfer of 2 × 10⁶ cells in conjunction with gp100-VV and IL-2 (n = 5 mice/group). NT no treatment. Data are representative of two independent experiments. **P < 0.01 (unpaired two-tailed Student’s t-test) (c, g, and h: left); ***P < 0.005 [a Log-rank (Mantel-Cox) Test] (h: right)